Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466
about
5-HT(6) receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophreniaAntidepressant and anxiolytic effects of selective 5-HT6 receptor agonists in ratsEffects of serotonin in the hippocampus: how SSRIs and multimodal antidepressants might regulate pyramidal cell function5-HT6 receptors and Alzheimer's diseaseThe serotonin 5-HT6 receptor: a viable drug target for treating cognitive deficits in Alzheimer's diseaseStudy of a mechanism responsible for potential antidepressant activity of EMD 386088, a 5-HT6 partial agonist in rats5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's diseaseSerotonin receptor expression in human prefrontal cortex: balancing excitation and inhibition across postnatal developmentThe Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptorsAltered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressantsBehavioral Biomarkers of Schizophrenia in High Drinker Rats: A Potential Endophenotype of Compulsive Neuropsychiatric Disorders.Effect of acute and chronic electroconvulsive shock on 5-hydroxytrypamine 6 receptor immunoreactivity in rat hippocampus.The BTBR mouse model of autism spectrum disorders has learning and attentional impairments and alterations in acetylcholine and kynurenic acid in prefrontal cortex.Alzheimer's disease and age-related memory decline (preclinical)Increased expression of 5-HT₆ receptors in dorsolateral striatum decreases habitual lever pressing, but does not affect learning acquisition of simple operant tasks in rats.Deconstructing 5-HT6 receptor effects on striatal circuit function.Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease.The role of serotonin receptor subtypes in treating depression: a review of animal studies5-HT6 receptor agonism facilitates emotional learning.5-HT(6) receptor agonists and antagonists enhance learning and memory in a conditioned emotion response paradigm by modulation of cholinergic and glutamatergic mechanisms.Serotonin 6 receptor controls Alzheimer's disease and depressionIncreased expression of the 5-HT6 receptor by viral mediated gene transfer into posterior but not anterior dorsomedial striatum interferes with acquisition of a discrete action-outcome task.Activation of 5-HT6 receptors modulates sleep-wake activity and hippocampal theta oscillationThe role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment.Role of serotonin in Alzheimer's disease: a new therapeutic target?Schedule-induced polydipsia as a model of compulsive behavior: neuropharmacological and neuroendocrine bases.The serotonin-6 receptor as a novel therapeutic target.5HT(6) receptor antagonists: a patent update. Part 1. Sulfonyl derivatives.Leading compounds for the validation of animal models of psychopathology.Pharmacological approaches for Alzheimer's disease: neurotransmitter as drug targets.Antidepressant-like activity of EMD 386088, a 5-HT6 receptor partial agonist, following systemic acute and chronic administration to rats.Investigational drugs targeting 5-HT6 receptors for the treatment of Alzheimer's disease.Emerging chemical therapies targeting 5-hydroxytryptamine in the treatment of Alzheimer's disease.Effects of ST1936, a selective serotonin-6 agonist, on electrical activity of putative mesencephalic dopaminergic neurons in the rat brain.The 5-HT6 receptor agonist EMD 386088 produces antidepressant and anxiolytic effects in rats after intrahippocampal administration.The 5-hydroxytryptamine (serotonin) receptor 6 agonist EMD 386088 ameliorates ketamine-induced deficits in attentional set shifting and novel object recognition, but not in the prepulse inhibition in rats.The frontal cortex as a network hub controlling mood and cognition: Probing its neurochemical substrates for improved therapy of psychiatric and neurological disorders.Dorsomedial prefrontal cortex 5-HT6 receptors regulate anxiety-like behavior.Comparative effects of sertraline, haloperidol or olanzapine treatments on ketamine-induced changes in mouse behaviours.Activation of serotonin 5-HT2A receptors inhibits high compulsive drinking on schedule-induced polydipsia.
P2860
Q24299992-1555F3FA-DEBE-4BD4-964A-4E6A9F606C8FQ24602751-341F4798-F672-4A65-AA3C-9A547D677E45Q26783101-B0001A82-92D7-49A7-AFBA-AFB34374090CQ27006820-8CBC391F-A54D-45E3-AF6C-2C35D3737AD0Q28251394-3739517A-D2FB-405C-91DA-D6724B618932Q28275114-005C9E3B-9CC6-4EF4-A385-93CC0B516B28Q28287100-C60FE579-3EDB-4147-8902-5F085DCC7130Q28741999-5A72856C-4425-440D-A7F7-838330629C14Q30486707-E64C3F02-422C-4B13-8AD6-D04CFBAA04A3Q30887852-9E70512A-9F4B-4B04-B7AF-79DB857F7F66Q33802768-4EF029F7-9FC8-483D-8183-3E6FC1715532Q34241575-D194A469-2D15-4821-A8B7-F0A3F61B9819Q34701031-EC6EB43B-4493-4F08-B903-6DC4AB2CBECBQ35041190-152C2682-D630-4F28-BFA2-EE6AC6DD7A92Q35112806-F2005F57-7310-4FE1-8595-3130C54C226BQ35688656-EA143B85-958B-495F-8ECE-F62EE27BC8ABQ36020776-896AC08F-5585-4348-9D2B-8F015D0DCB62Q36031101-A3FD8623-6887-4FF6-A041-27C3A45A8D49Q36097366-2154CB1A-2050-4601-84F8-650F6B853463Q36346938-33E1D203-EF04-42DB-B382-E3A08E1570B8Q36413592-39A0D859-C2AB-4264-97A3-430648715F4EQ36490844-108C417B-C950-44D2-9638-F32EAC18A132Q36540905-EDD8B939-98B5-4006-A1D8-914697099609Q37826638-6F47865D-1E06-45C9-9E71-DF4892AED8A5Q37922766-61D3DD84-5DF8-4115-A80A-9FDCE75996D3Q37960352-1A47B821-4D97-43BF-9630-CF7610EDAE10Q37987116-9469F094-3C7B-4895-B09C-F8DFFBF4ACC9Q38027891-A7D4A8B2-978B-4B77-9D38-CF33BA455695Q38128733-C508186E-8EA4-4203-B01D-0AA270786F5DQ38286222-A71E8C83-BF56-42E4-AC1B-A194358CFFB0Q38298300-EDA84A6E-5E95-42D9-B35E-ED99A684B12AQ38627971-DE9E4FDD-06FB-4E0B-A373-2430F562A255Q39158422-61433A54-ABD8-461C-A493-620871A61309Q41307502-ECFEAE65-1145-4A3F-B2B4-EDEDDF005C11Q42597841-01728C55-C91B-430D-BB14-9906020D2F4BQ44655683-046D3159-974C-4DE8-97EF-34E1EFDF7C83Q47382890-8F4BC523-EBBC-403D-A8CF-8913CFC457DCQ47587262-CEE8A21B-44D3-45F9-84F2-0B2539771DCBQ47869087-FE7374A5-8A94-44F0-9E5E-39ECC186EA47Q48586285-ECB0FA39-8312-4663-A676-0951F87A96B9
P2860
Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Neuropharmacological profile o ...... sts: WAY-181187 and WAY-208466
@ast
Neuropharmacological profile o ...... sts: WAY-181187 and WAY-208466
@en
Neuropharmacological profile o ...... sts: WAY-181187 and WAY-208466
@nl
type
label
Neuropharmacological profile o ...... sts: WAY-181187 and WAY-208466
@ast
Neuropharmacological profile o ...... sts: WAY-181187 and WAY-208466
@en
Neuropharmacological profile o ...... sts: WAY-181187 and WAY-208466
@nl
prefLabel
Neuropharmacological profile o ...... sts: WAY-181187 and WAY-208466
@ast
Neuropharmacological profile o ...... sts: WAY-181187 and WAY-208466
@en
Neuropharmacological profile o ...... sts: WAY-181187 and WAY-208466
@nl
P2093
P2860
P3181
P356
P1476
Neuropharmacological profile o ...... sts: WAY-181187 and WAY-208466
@en
P2093
Albert Robichaud
Brian Platt
Chad E Beyer
Deborah L Smith
Derek Cole
Guoming Zhang
Lee A Dawson
Lee E Schechter
Michael R Brandt
P2860
P2888
P304
P3181
P356
10.1038/SJ.NPP.1301503
P407
P577
2008-05-01T00:00:00Z
P5875
P6179
1052422555